Navigation Links
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Date:6/16/2009

Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company

FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the first of a planned 235 subjects into a Phase II dose response study investigating an experimental, cell-based wound therapy ---HP802-247---intended for the treatment of venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The first patient was enrolled at The Center for Clinical Research near San Francisco, Calif., led by the site's principal investigator, Alexander Reyzelman, DPM. The study is being conducted by 28 investigators in 18 states.

"The start of enrollment into this multi-center, randomized trial is an important milestone for HEALTHPOINT," said Bert Slade, M.D., FAAAAI, Chief Medical Officer at HEALTHPOINT and co-author of the trial protocol. "This is the largest cell therapy dose ranging trial ever undertaken in the area of wound healing."

The trial is the second of two planned-dose response trials, extending the dose range being tested and exploring two plausible dose frequencies. Enrollment into the trial is preceded by screening and run-in phases and is expected to continue through the middle of 2010. The first trial showed promising results over a four-fold range of cell concentrations administered weekly.

This trial is evaluating the benefits and safety of enhancing wound healing by using metabolically active donor cells to support the patient's own skin cells' healing ability. HP802-247 utilizes allogeneic cells, which are living human cells derived from an individual donor that are subsequently grown in a tissue culture, and then applied to an unrelated patient. The HP802-247 product consists of both keratinocytes and fibrobl
'/>"/>

SOURCE HEALTHPOINT, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
3. MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
4. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
9. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
10. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
11. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... CHADDS FORD, Pa., July 10 ... Pharmaceuticals (Nasdaq: ENDP ) jointly announced today that ... and market Urocidin(TM) in the U.S. with an option for ... Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the ...
... , ALEXANDRIA, Va., July 9 The world-wide explosion of ... of obesity is widely recognized. Could it really be an ... over the increasing prevalence of overweight conditions in our society, ... as a potential direct contributor to obesity. , ...
Cached Medicine Technology:Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) 2Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) 3Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) 4Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) 5Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) 6Is Obesity an Oral Bacterial Disease? 2
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... N.C. April 17, 2014 Meaningful long-term ... advanced cancer of the abdomen when treated with ... according to a first-of-its-size analysis by physicians at ... Baptist has the largest reported, single-center experience with ... A. Levine, M.D., and analysis of 20 years, ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... ... Cost Savings , ... Canton, MA (PRWEB) April 19, 2010 -- TriNET Systems today announced the availability of ... of service and support options while helping to reduce operating costs. Sentinel is ...
... ... selling their premium brand electronic cigarettes via the internet. , ... Reno, NV (PRWEB) April 18, 2010 -- ... electronic cigarettes via the internet. Previously, Freedom was sold exclusively through retail outlets. ...
... ... learn to use bioinformatics and genomics resources with the extensive tutorial suite catalog from OpenHelix. ... (PRWEB) April 19, 2010 ... a subscription to OpenHelix ( www.openhelix.com ) giving NIH scientists and staff access ...
... ... initiated a bladder cancer testing program for active and retireed firefighters. The ... or retiree events using the NMP22 BladderChek test. According to the foundation, ... part of a larger study. The educational message urges men and women ...
... ... Foundation. , ... OH (PRWEB) April 19, 2010 -- Mark Jenney, an Ohio-area philanthropist and entrepreneur, made ... is to ensure that research is done to help prevent and control the disease, and ...
... ... attorney Van Irion filed a national class action in Federal court. The suit challenges Obamacare ... Mr. Irion is asking the courts to re-evaluate the Commerce clause precedent, arguing that current ... , ...
Cached Medicine News:Health News:TriNET Launches New Managed Services Offering 2Health News:Freedom Smokeless Electronic Cigarette Sales Are Smoke ‘N 2Health News:National Institutes of Health subscribes to OpenHelix training portal 2Health News:National Institutes of Health subscribes to OpenHelix training portal 3Health News:San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway 2Health News:San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway 3Health News:Over 10,000 Americans Join Lawsuit Against Obamacare 2Health News:Over 10,000 Americans Join Lawsuit Against Obamacare 3
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Round knurled handle. Overall length 130 mm....
Medicine Products: